J2170 Mecasermin injection
Also known as: mecasermin, Increlex, IGF-1
Injection of mecasermin. A recombinant insulin-like growth factor-1 for growth hormone insensitivity syndrome.
In Plain Language
growth hormone supplement; growth factor injection
Clinical Context
Used for growth hormone insensitivity syndrome and severe insulin-like growth factor-1 deficiency. Promotes growth and metabolic effects.
RVU Information
CPT J2170 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J2170?
CPT J2170 (Mecasermin injection) is a J Codes (Drugs) code. Injection of mecasermin. A recombinant insulin-like growth factor-1 for growth hormone insensitivity syndrome.
How is J2170 administered?
CPT J2170 is administered by a healthcare provider, typically via injection or infusion. Used for growth hormone insensitivity syndrome and severe insulin-like growth factor-1 deficiency. Promotes growth and metabolic effects. It is used by Endocrinology, Pediatrics, Genetics.
When is CPT J2170 used?
Used for growth hormone insensitivity syndrome and severe insulin-like growth factor-1 deficiency. Promotes growth and metabolic effects.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.